Go Pro
NASDAQ:TXG

10x Genomics (TXG) Stock Price, News & Analysis

10x Genomics logo
$57.99 +1.90 (+3.39%)
As of 04:00 PM Eastern

About 10x Genomics Stock (NASDAQ:TXG)

Advanced

Key Stats

Today's Range
$55.62
$58.74
50-Day Range
$28.84
$58.57
52-Week Range
$11.16
$60.69
Volume
2.26 million shs
Average Volume
3.05 million shs
Market Capitalization
$7.56 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$38.31
Consensus Rating
Hold

Company Overview

10x Genomics, Inc. is a biotechnology company specializing in advanced genomic analysis solutions that enable researchers to explore biology at unprecedented resolution. The company develops and manufactures integrated hardware, consumables and software products for single-cell sequencing and spatial genomics. Its flagship Chromium product line supports applications in single-cell RNA sequencing, immune profiling and genome assembly, while the Visium and Xenium platforms offer spatial transcriptomics and in situ analysis, respectively.

Founded in 2012 and headquartered in Pleasanton, California, 10x Genomics serves a global customer base that includes academic institutions, pharmaceutical and biotechnology companies, and government research organizations. The company has established regional operations and support centers across North America, Europe and Asia to facilitate training, technical support and collaborations with leading research laboratories.

10x Genomics has built its reputation on enabling new discoveries in fields such as oncology, immunology, neuroscience and developmental biology. By combining microfluidics, novel chemistry and bioinformatics software, the company’s solutions aim to simplify workflow complexity and accelerate data generation and interpretation for large-scale studies.

Co-founded by Serge Saxonov, Ben Hindson and Kevin Ness, 10x Genomics continues to expand its product portfolio through ongoing research and development. The company’s integrated approach to single-cell and spatial biology is designed to empower scientists worldwide to uncover cellular heterogeneity, identify therapeutic targets and drive innovation in precision medicine.

AI Generated. May Contain Errors.

10x Genomics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
34th Percentile Overall Score

TXG MarketRank™: 

10x Genomics scored higher than 34% of companies evaluated by MarketBeat, and ranked 746th out of 912 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    10x Genomics has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on no strong buy ratings, 5 buy ratings, 10 hold ratings, and 1 sell rating.

  • Downside Risk

    10x Genomics has a consensus price target of $38.31, representing about 33.9% downside from its current price of $57.99.

  • Amount of Analyst Coverage

    10x Genomics has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about 10x Genomics' stock forecast and price target.
  • Earnings Growth

    Earnings for 10x Genomics are expected to grow in the coming year, from ($0.79) to ($0.64) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of 10x Genomics is -98.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of 10x Genomics is -98.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    10x Genomics has a P/B Ratio of 9.29. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about 10x Genomics' valuation and earnings.
  • Percentage of Shares Shorted

    13.50% of the float of 10x Genomics has been sold short.
  • Short Interest Ratio / Days to Cover

    10x Genomics has a short interest ratio ("days to cover") of 5.79.
  • Change versus previous month

    Short interest in 10x Genomics has recently decreased by 3.86%, indicating that investor sentiment is improving.
  • Dividend Yield

    10x Genomics does not currently pay a dividend.

  • Dividend Growth

    10x Genomics does not have a long track record of dividend growth.

  • News Sentiment

    10x Genomics has a news sentiment score of 0.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 9 news articles for 10x Genomics this week, compared to 6 articles on an average week.
  • Search Interest

    14 people have searched for TXG on MarketBeat in the last 30 days. This is an increase of 367% compared to the previous 30 days.
  • MarketBeat Follows

    7 people have added 10x Genomics to their MarketBeat watchlist in the last 30 days. This is an increase of 250% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, 10x Genomics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,736,357.00 in company stock.

  • Percentage Held by Insiders

    8.84% of the stock of 10x Genomics is held by insiders.

  • Percentage Held by Institutions

    84.68% of the stock of 10x Genomics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about 10x Genomics' insider trading history.
Receive TXG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for 10x Genomics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

TXG Stock News Headlines

5 Revealing Analyst Questions From 10x Genomics’s Q2 Earnings Call
10x Genomics (TXG) Receives a Buy from Stifel Nicolaus
Trump's New Dollar
Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.tc pixel
10x Genomics (TXG) Gets a Buy from Stephens
See More Headlines

TXG Stock Analysis - Frequently Asked Questions

10x Genomics' stock was trading at $16.31 at the beginning of 2026. Since then, TXG stock has increased by 255.5% and is now trading at $57.99.

10x Genomics (NASDAQ:TXG) posted its quarterly earnings results on Thursday, August, 6th. The company reported ($0.14) earnings per share for the quarter, beating analysts' consensus estimates of ($0.24) by $0.10. 10x Genomics's revenue for the quarter was down 12.7% compared to the same quarter last year.
Read the conference call transcript
.

10x Genomics (TXG) raised $370 million in an initial public offering on Thursday, September 12th 2019. The company issued 10,000,000 shares at $36.00-$38.00 per share. J.P. Morgan, Goldman Sachs and BofA Merrill Lynch served as the underwriters for the IPO and Cowen was co-manager.

Top institutional investors of 10x Genomics include Mirador Capital Partners LP (0.05%), Versant Capital Management Inc (0.02%), Tactive Advisors LLC (0.01%) and Regent Peak Wealth Advisors LLC (0.01%). Insiders that own company stock include Serge Saxonov, Benjamin J Hindson, Adam Taich, John R Stuelpnagel, Justin J Mcanear, James Wilbur, Alan Mateo and Shehnaaz Suliman.
View institutional ownership trends
.

Shares of TXG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that 10x Genomics investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), PayPal (PYPL), Advanced Micro Devices (AMD) and CrowdStrike (CRWD).

Company Calendar

Last Earnings
8/06/2026
Today
8/17/2026
Next Earnings (Estimated)
11/05/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Life Sciences Tools & Services
Sub-Industry
Life Sciences Tools & Services
Current Symbol
NASDAQ:TXG
CIK
1770787
Fax
N/A
Employees
1,240
Year Founded
2012

Price Target and Rating

High Price Target
$65.00
Low Price Target
$17.00
Potential Upside/Downside
-33.9%
Consensus Rating
Hold
Rating Score (0-4)
2.25
Research Coverage
16 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.59)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$43.54 million
Net Margins
-12.18%
Pretax Margin
-12.14%
Return on Equity
-9.33%
Return on Assets
-7.30%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
5.69
Quick Ratio
5.25

Sales & Book Value

Annual Sales
$642.82 million
Price / Sales
11.75
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$6.24 per share
Price / Book
9.29

Miscellaneous

Outstanding Shares
130,290,000
Free Float
118,773,000
Market Cap
$7.56 billion
Optionable
Optionable
Beta
2.03

Social Links

7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

This page (NASDAQ:TXG) was last updated on 8/17/2026 by MarketBeat.com Staff.
From Our Partners